Michael Sketch is a Cardiology physician affiliated with Duke Medical Center. OpenAlex indexes 231 publications with 7,148 citations (h-index 45).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
91%Adenosine Receptor Agonist28.3%Regadenoson100%Part B, office-administered≥26 patientsStatin17.1%Rosuvastatin Calcium52%Atorvastatin Calcium48%Part D≥17 patients+ 6 more classes in this area
Blood & clotting
9%Factor Xa inhibitor9%Eliquis55%Xarelto46%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Identifying the Infarct-Related Artery in Patients With Non–ST-Segment–Elevation Myocardial Infarction
Circulation Cardiovascular Interventions
2019 - A Guide for a Cardiovascular Genomics Biorepository: the CATHGEN Experience
Journal of Cardiovascular Translational Research
2015 - Three-Year Outcomes Associated With Embolic Protection in Saphenous Vein Graft Intervention
Circulation Cardiovascular Interventions
2015 - Association of Anxiety and Depression With All‐Cause Mortality in Individuals With Coronary Heart Disease
Journal of the American Heart Association
2013 - The “Final” 5-Year Follow-Up From the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent With a Paclitaxel-Eluting Stent
JACC: Cardiovascular Interventions
2013
Similar KOLs
Other experts from the same institution or the same specialty.
James Abbruzzese, MD
Duke Medical Center
David Durack, MD
Duke Medical Center
Leonard Prosnitz, MD
Duke Medical Center
Scott Cousins, MD
Duke Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”